Gallbladder cancer starts in the gallbladder. Cholangiocarcinoma, also called bile duct cancer, starts in the ducts that carry bile within or outside the liver. Both are biliary tract cancers, but the exact site determines what surgery would involve, how a biopsy should be obtained, and which biomarkers may guide treatment. Surgery is the main treatment with the aim of cure when the cancer can be removed completely. When surgery is unsuitable or the cancer has spread, treatment may include chemotherapy, immunotherapy, targeted therapy, and procedures to relieve bile duct blockage. [1–4]
By Dr Raman Narang, Consultant Medical & Hemato-Oncologist, New Delhi
Two situations often bring patients to a biliary cancer consultation. One is a pathology report that unexpectedly finds cancer after an operation for gallstones. The other is a scan done for jaundice that shows a blockage in the bile duct. The next step can be quite different. If you are seeking gallbladder cancer or bile duct cancer treatment in Delhi, bring the original scan images and any operation or procedure records. They can change what the team recommends first.
1. What is the difference between gallbladder cancer and bile duct cancer?
The gallbladder stores bile. The bile ducts carry bile from the liver to the small intestine. Most cancers that start in the gallbladder or bile ducts are adenocarcinomas. Cholangiocarcinoma is classified by where along the bile ducts it begins. [1–3]
| Type | Where it starts | Why the location matters |
|---|---|---|
| Gallbladder cancer | In the gallbladder wall | It can be found unexpectedly after gallbladder removal. The depth of invasion and surgical margins help determine whether another operation is needed. |
| Intrahepatic cholangiocarcinoma | In bile ducts inside the liver | It often appears as a liver mass. If removable, treatment usually involves liver surgery. Certain biomarkers, including FGFR2 fusions and IDH1mutations, are particularly relevant in advanced disease. |
| Perihilar cholangiocarcinoma | Where the main right and left bile ducts join near the liver | It can cause jaundice. The team must map which ducts and blood vessels are involved and assess how much functioning liver would remain after surgery. |
| Distal cholangiocarcinoma | In the lower bile duct, near or within the pancreas | It can cause jaundice and may resemble a pancreatic head tumour on initial imaging. A Whipple procedure may be considered when it can be removed. |
2. What symptoms and risk factors should you know about?
Gallbladder cancer can cause persistent pain in the upper right abdomen, nausea, loss of appetite, or unexplained weight loss. It may also be found when a gallbladder removed for presumed gallstone disease is examined under a microscope. Gallstones are a risk factor, but most people with gallstones never develop gallbladder cancer. [1]
Bile duct cancer can cause yellowing of the eyes or skin, dark urine, pale stools, or itching when bile flow is blocked. Cancers that start within the liver may instead cause abdominal discomfort, weight loss, or few symptoms at first. Risk factors include primary sclerosing cholangitis, certain congenital bile duct abnormalities, and some chronic liver or bile duct conditions. Many people have no identifiable risk factor. [2, 3]
New jaundice warrants prompt medical assessment. Jaundice with fever, chills, or worsening abdominal pain needs urgent assessment because it may indicate an infection in a blocked bile duct. [2, 3]
3. How are gallbladder and bile duct cancers diagnosed and staged?
An ultrasound is often the first scan when someone has jaundice or upper abdominal pain. Contrast CT and MRI with MRCP, which maps the bile ducts, help show where the abnormality starts, whether major blood vessels are involved, and whether the cancer has spread. Blood tests assess bilirubin and liver function. CA 19-9 can provide additional information, but bile duct blockage or infection can raise it, so it is interpreted alongside imaging and other blood tests. [2, 3]
Tissue confirmation is generally needed before starting systemic treatment. How tissue is obtained matters. Depending on the site, the team may use samples taken during ERCP, endoscopic ultrasound, or an image-guided biopsy. ERCP can also allow a stent to be placed to relieve a blockage. For a potentially removable perihilar or distal bile duct cancer, consult the hepatobiliary team before arranging a needle biopsy through the skin. The sampling route can affect surgical or transplant options in selected cases. [2, 3]
4. When is surgery done first, and when is another operation needed?
When scans suggest that the cancer can be removed completely and the patient is fit for the operation, surgery first is often the preferred approach. The team considers the tumour’s location, the extent of spread along the bile ducts, blood vessel involvement, and whether enough functioning liver will remain after surgery. [1–3]
If gallbladder cancer was found after surgery for gallstones, the first step is to review the pathology and operation report. A T1a tumour, confined to the inner connective tissue layer and completely removed with clear margins, can often be managed with the original gallbladder operation alone. T1b means the tumour has reached the muscle layer. For T1b or deeper disease, a specialist team generally assesses whether a completion operation is appropriate after staging. This may include removing nearby liver tissue and regional lymph nodes. [1, 3]
For bile duct cancer, the operation depends on the site. Intrahepatic tumours may require removal of part of the liver. Perihilar tumours often require complex surgery involving the bile ducts and part of the liver. A distal bile duct tumour may be treated with a Whipple procedure. Liver transplantation is an option only for carefully selected patients with perihilar cholangiocarcinoma under specialised protocols. [2, 3]
After surgery, capecitabine, an oral chemotherapy, is commonly discussed for eligible patients with resected biliary tract cancer. The final pathology, including lymph node involvement and whether the margins are clear, helps guide the postoperative plan. Radiation or chemoradiation may be considered in selected cases, particularly after removal of an extrahepatic bile duct or gallbladder cancer with a microscopically positive margin. [3, 5]
5. How are locally advanced and metastatic biliary tract cancers treated?
Locally advanced disease can be unsuitable for surgery even when there is no distant spread. The team usually starts with systemic treatment. If the cancer responds well, a specialist team can reassess whether surgery or another local treatment has become feasible. Radiation or a liver-directed procedure may be considered for selected patients, depending on where the disease is and what the treatment is intended to achieve. [2–4]
For unresectable or metastatic gallbladder cancer or cholangiocarcinoma, gemcitabine plus cisplatin with either durvalumab or pembrolizumab is a first-line option for eligible patients. Kidney function, liver function, bile duct drainage, and overall fitness affect which regimen is appropriate. If the cancer progresses, the next choice may be another chemotherapy regimen, such as FOLFOX, a biomarker-matched treatment, or a clinical trial where available. [3, 4]
Which biomarkers can change treatment?
For advanced biliary tract cancer, molecular profiling is best discussed before or during first-line treatment so that results are available when the next decision arises. [3, 4]
| Finding | How it can guide treatment |
|---|---|
| FGFR2 fusion or rearrangement | Seen mainly in intrahepatic cholangiocarcinoma. An FGFR inhibitor may be an option after prior treatment. |
| IDH1 mutation | More often seen in intrahepatic cholangiocarcinoma. Ivosidenib may be considered in an appropriate later-line setting. |
| HER2 positivity | Particularly relevant in gallbladder cancer and some extrahepatic bile duct cancers. The exact HER2 test result can help determine eligibility for a HER2-directed treatment. |
| MSI-high or mismatch repair deficiency | An uncommon finding that can support immunotherapy in selected settings. It answers a different question from eligibility for standard first-line chemoimmunotherapy. |
The specific result, prior treatment, and applicable Indian prescribing indication and access all matter. Symptom care can begin alongside cancer treatment and may include bile duct drainage, pain relief, treatment for itching, and nutrition support. [2–4]
What I look for clinically before recommending treatment
I first establish where the cancer started and what makes it removable or unsuitable for surgery. After an unexpected gallbladder cancer diagnosis, I check how deeply the tumour invaded, whether the margins were clear, and what the first operation involved. With a bile duct tumour, I review the imaging and bilirubin trend to see whether drainage or treatment of infection needs to come first. For advanced disease, I check whether there is enough tissue for molecular testing before the results are needed to make a decision.
How the next step is decided
| If the reports show… | The next discussion is about… |
|---|---|
| Completely removed T1a gallbladder cancer | Whether the original operation is sufficient and what follow-up is appropriate |
| Incidental T1b or deeper gallbladder cancer | Staging and assessment for completion surgery |
| A potentially removable bile duct cancer | The operation, biopsy strategy, and whether drainage is needed beforehand |
| A blocked bile duct with suspected infection | Urgent management of the blockage and infection |
| Locally advanced disease without distant spread | Initial systemic treatment and when to reassess for surgery or local treatment |
| Metastatic or recurrent disease | Systemic treatment, molecular testing, and symptom control |
What to bring to a biliary cancer consultation in Delhi
- Ultrasound, contrast CT, and MRI/MRCP reports and the original images.
- Biopsy or gallbladder pathology report, including tumour depth and margins if reported.
- Operation notes if the gallbladder has already been removed.
- ERCP, bile duct stent, or drainage records, including procedure dates.
- Recent bilirubin, liver function, kidney function, and CA 19-9 results, if available.
- Molecular profiling or HER2 reports and a summary of any treatment already received.
Frequently asked questions
Does jaundice mean the cancer has spread?
Jaundice can occur because a tumour blocks bile flow, even when the cancer is localised. Imaging determines the extent of disease and helps the team decide whether drainage is needed. [2, 3]
Does everyone with cancer found after gallbladder removal need another operation?
A completely removed T1a tumour can often be managed with the original operation alone. For T1b or deeper disease, the team reviews the pathology and scans to decide whether completion surgery is appropriate. [1, 3]
Does everyone with a blocked bile duct need a stent before surgery?
Drainage is individualised. The team considers infection, symptoms, bilirubin levels, the location of the blockage, and how soon surgery or chemotherapy is planned. [2, 3]
When should I ask about molecular testing?
If the cancer is unresectable, metastatic, or recurrent, ask early whether there is enough tissue for testing and which results could change the next treatment. [3, 4]
At your consultation, ask the team to write down the exact cancer site, whether it can be removed completely, and which finding determines the first step. If surgery is unsuitable today, ask what would prompt a surgical reassessment and which biomarker results could influence later treatment.
This page is for general education. Individual treatment decisions require review of your scans, pathology, liver function, and overall health by your treating team.
Clinical references
- National Cancer Institute. Gallbladder Cancer Treatment (PDQ), Health Professional Version.
- National Cancer Institute. Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ), Health Professional Version.
- ESMO. Pan-Asian Adapted Clinical Practice Guidelines for the Diagnosis, Treatment and Follow-up of Patients with Biliary Tract Cancer.
- ESMO. Clinical Practice Guideline Interim Update on the Management of Biliary Tract Cancer.
- Bridgewater J and colleagues. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.